Onkologie. 2010:4(1):18-23

Treatment of gastrointestinal stromal tumours

Zdeněk Linke, Jana Prausová
Radioterapeuticko-onkologické oddělení FN Motol, Praha

The article deals with possibilities of gastrointestinal stromal tumour therapy – one of the first solid tumour, whose chemical and radiation

treatment was completely displaced by biologic treatment. Imatinib mesylát represents primary target treatment of progressed

inoperable gastrointestinal stromal tumour. Except overview of clinical studies and treatment results the article responses to controversial

questions – initial imatinib dosage, predictive factors, which cal lead to standards primary dosage escalation, question of treatment

continuation after complete remission. The article also refers to others possibilities continuation in biological target therapy even after

imatinib failure – use of sunitinib, nilotinib, mTOR perspective IPI-504.

Keywords: gastrointestinal stromal tumour, imatinib, nilotinib, mTOR inhibitor

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Linke Z, Prausová J. Treatment of gastrointestinal stromal tumours. Onkologie. 2010;4(1):18-23.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Matteo R, Owzar K, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001; ASCO 2007.
    2. Blanke C. Evaluation of the Safety and Efficacy of an Oral Molecularly-Targeted Therapy, STI571, in Patients (Pts) with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GISTS) Expressing C-KIT (CD117). ASCO Annual Meeting, abstract 1.
    3. Van Oosterom, et al. Update of the Imatinib (STI571, Glivec) phase I study in gastro intestinal stromal tumours (GISTs). ASCO 2001, abstract 327.
    4. Blanke C, Demetri G, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. NEJM, 2002; 347: 472-480. Go to original source... Go to PubMed...
    5. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY. Progression free survival in gastrointestinal stromal tumor with high a low dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134. Go to original source... Go to PubMed...
    6. Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher ClD, Bramwell V. Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033 (abstract 9005), Proc ASCO 2004; 23: 815. Go to original source...
    7. Van Glabbeke M, Verweij J, et al. Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumor are predicted by different prognostic factors, an eortc-isg-agitg study. J Clin Oncol 2005; 23: 5795-5804. Go to original source... Go to PubMed...
    8. Blay JY, Le Cesne A, et al. Prospective Multicenter Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarmoma Group. J Clin Oncol 25: 1107-1113. Go to original source... Go to PubMed...
    9. ios M, La Cesne A, et al. Interruption of imatinib in GIST patients with advanced diasease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. ASCO Ann Meet 2007, abstract 10016. Go to original source...
    10. Rutkowski P, et al. The outcomes of imatinib therapy gastrointestinal stromal tumors (GISTs) originating from the small bowel. ASCO Ann Meet 2007, abstract 10052. Go to original source...
    11. Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta - metaanalysis based on 1.640 patients. ASCO Ann Meet 2007, abstract 10004. Go to original source...
    12. Cioffi A, Emile JF, Domont J, et al. Long term progression-free-survival correlates with KIT/PDGFR mutational status in advanced GIST patients treated with imatinib (IM). ASCO Ann Meet 2007, abstract 10053. Go to original source...
    13. Bulusu VR, Jephcott CR, Fawcett S, Cook N, et al. RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumors on imatinib mesylate. Cambridge GIST study group experience. J Clin Oncol, 2007 ASCO Meet Proceed Part I, Vol 25, No 18S (June 20 Suppl), 2007: 10019. Go to original source...
    14. HeindrichMC, Maki RG, Corless CL, et al. Sunitinib response in imatinib - resistant GIST correlates with KIT and PDGFR mutation status. J Clin Oncol 2006; 24: 9502. Go to original source...
    15. Demetri GD, van Oosterom AT, et al. Efficacy and safety of sunitinib in patients with advanced gastointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006: 6736-6746. Go to original source... Go to PubMed...
    16. Van Oosterom AT, Dumez H, Desai J, et al. Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate in patients with gastrointestinal stromal tumors refractory to imatinib mesylate. J Clin Oncol 2004, 22: 3002. Go to original source...
    17. Demetri GD. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. 2007 ASCO Annual Meeting, Sarcoma. Go to original source...
    18. Reichardt P, Casali PG, Blay J, Von Mehren M. A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). 2006 ASCO Annual Meeting. Go to original source...
    19. El-Rifai, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumor: tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-3903. Go to PubMed...
    20. Data on file, Novartis UK Ltd. Study No STI571B2222. Open, randomized, phase II study of Glivec in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing c-kit. Report 15th December 2003.
    21. Von Mehren M, Reichardt P, Casali PG, Blay J. A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study Update. 2007 ASCO Meeting. Go to original source...
    22. Zhan A, et al. Presented at: ASCO 2007, June 1-5, Chigaco; III; Abstract 10045.
    23. Clinical trial SSG XVIII; Available at: http://clinicaltrials.gov/ct/show/NCT00116935.
    24. CAMN107A2201; www.ClinicalTrials.gov.indentifier: NCT00471326. Accessed October 26, 2009.
    25. CAMN107G2301; www.ClinicalTrials.gov.indentifier: NCT00785785. Accessed October 26, 2009.
    26. CAMN107DDE06; www.ClinicalTrials.gov.indentifier: NCT00756509. Accessed December 4, 2009.
    27. CAMN107DBR01; www.ClinicalTrials.gov.indentifier: NCT00751036. Accessed October 26, 2009.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.